Variation in the Urokinase-Plasminogen Activator Gene Does Not Explain the Chromosome 10 Linkage Signal for Late Onset AD

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 124 B, Issue 1, 2004, Pages 29-37

  Myers, Amanda J ^a,c   Marshall, Helen ^a   Holmans, Peter ^b   Compton, Danielle ^c   Crook, Richard J P ^d   Mander, Adrian P ^e   Nowotny, Petra ^a   Smemo, Scott ^a   Dunstan, Melanie ^f   Jehu, Luke ^d,f   Wang, Jen C ^a   Hamshere, Marian ^f   Morris, John C ^a   Norton, Joanne ^a   Chakraventy, Sumi ^a   Tunstall, Nigel ^g   Lovestone, Simon ^g   Petersen, Ronald ^h   O'Donovan, Michael ^f   Jones, Lesley ^f   Williams, Julie ^f   Owen, Michael J ^f   Hardy, John ^c   Goate, Alison ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MAYO CLINIC   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h MAYO CLINIC   (United States)

Author keywords

Alzheimer disease; Association study; Candidate gene; PLAU; Urokinase plasminogen activator

Indexed keywords

UROKINASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CASE CONTROL STUDY; CHROMOSOME 10; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PLAU GENE; PRIORITY JOURNAL;

EID: 0346102515     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.20036     Document Type: Article

References (21)

1. Bader JS. 2001. The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2(1):11-24.
2. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. 1992. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360(6405):672-674.
3. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, JohnsonWood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3(1):67-72.
4. Clayton D. 1999. A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am J Hum Genet 65(4):1170-1177.
5. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB. 2000. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97(19):10483-10488.
6. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290(5500):2303-2304.
7. Hedrick PW. 1987. Gametic disequilibrium measures: Proceed with caution. Genetics 117(2):331-341.
8. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97(6):2892-2897.
9. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99-102.
10. Kwon JM, Nowotny P, Shah PK, Chakraverty S, Norton J, Morris JC, Goate AM. 2000. Tau polymorphisms are not associated with Alzheimer's disease. Neurosci Lett 284(1-2):77-80.
11. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. 2000. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1(6):530-535.
12. Mander AP. 2001. Haplotype analysis in population-based association studies. Stata J 1(1):57-73.
13. Muller-Myhsok B, Abel L. 1997. Genetic analysis of complex diseases. Science 275(5304):1328-1329; discussion 1329-1330.
14. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM. 2000. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290(5500):2304-2305.
15. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Knowles H, Morris JC, Williams N, Norton N, Abraham R, Kehoe P, Williams H, Rudrasingham V, Rice F, Giles P, Tunstall N, Jones L, Lovestone S, Williams J, Owen MJ, Hardy J, Goate A. 2002. Full genome screen for Alzheimer disease: Stage II analysis. Am J Med Genet 114(2):235-244.
16. Nanbu R, Menoud PA, Nagamine Y. 1994. Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 14(7):4920-4928.
17. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2(8):864-870.
18. Schork NJ, Fallin D, Lanchbury JS. 2000. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet 58(4):250-264.
19. Selkoe DJ. 2001. Clearing the brain's amyloid cobwebs. Neuron 32(2):177-180.
20. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. 2000. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem 75(5):2172-2177.
21. Yoshimoto M, Ushiyama Y, Sakai M, Tamaki S, Hara H, Takahashi K, Sawasaki Y, Hanada K. 1996. Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. Biochem et Biophys Acta 1293:83-89.